Literature DB >> 8518608

Research samples from families with genetic diseases: a proposed code of conduct.

P S Harper1.   

Abstract

Research on samples from families with genetic disease underlies many of the major advances that are occurring in medical genetics. But ethical and practical problems may arise when samples from relatives who are healthy but at risk are included in such studies. In particular, new molecular tests for specific gene mutations may result in the detection of a genetic defect in relatives who had neither expected this possibility nor given specific consent to such testing. Family members at risk should not be included in such studies unless strictly necessary, and in such cases specific consent should be obtained and information should be given about the implications of an abnormal result of a test. This is particularly important when stored samples from previous studies without such implications are being reused and is also relevant to the genetic testing of samples taken primarily for epidemiological studies of disorders when only a small proportion of cases is thought to be genetic in origin. There is a need for guidelines to protect both subjects and investigators in a field which is spreading rapidly and involving many clinical and laboratory research workers previously unfamiliar with genetic testing.

Entities:  

Keywords:  Biomedical and Behavioral Research; Genetics and Reproduction

Mesh:

Year:  1993        PMID: 8518608      PMCID: PMC1677780          DOI: 10.1136/bmj.306.6889.1391

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  8 in total

Review 1.  Seminars in medicine of the Beth Israel Hospital, Boston. beta-Amyloid and the pathogenesis of Alzheimer's disease.

Authors:  B A Yankner; M M Mesulam
Journal:  N Engl J Med       Date:  1991-12-26       Impact factor: 91.245

2.  Problems in genetic prediction for Huntington's disease.

Authors:  M J Morris; A Tyler; L Lazarou; L Meredith; P S Harper
Journal:  Lancet       Date:  1989-09-09       Impact factor: 79.321

3.  Guidelines for DNA banking. Report of the Clinical Genetics Society working party on DNA banking.

Authors:  J R Yates; S Malcolm; A P Read
Journal:  J Med Genet       Date:  1989-04       Impact factor: 6.318

Review 4.  Molecular biology of prion diseases.

Authors:  S B Prusiner
Journal:  Science       Date:  1991-06-14       Impact factor: 47.728

5.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.

Authors:  S Srivastava; Z Q Zou; K Pirollo; W Blattner; E H Chang
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

6.  Diagnosis of Duchenne muscular dystrophy: experiences of parents of sufferers.

Authors:  M A Firth
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-26

7.  Presymptomatic diagnosis of delayed-onset disease with linked DNA markers. The experience in Huntington's disease.

Authors:  J Brandt; K A Quaid; S E Folstein; P Garber; N E Maestri; M H Abbott; P R Slavney; M L Franz; L Kasch; H H Kazazian
Journal:  JAMA       Date:  1989-06-02       Impact factor: 56.272

8.  Genetic testing and insurance.

Authors:  P S Harper
Journal:  J R Coll Physicians Lond       Date:  1992-04
  8 in total
  4 in total

Review 1.  Genetic research, adolescents, and informed consent.

Authors:  R F Weir; J R Horton
Journal:  Theor Med       Date:  1995-12

2.  The genetic testing of children. Working Party of the Clinical Genetics Society (UK)

Authors:  A Clarke
Journal:  J Med Genet       Date:  1994-10       Impact factor: 6.318

3.  Disclosure of genetics research results after the death of the patient participant: a qualitative study of the impact on relatives.

Authors:  E Ormondroyd; C Moynihan; M Watson; C Foster; S Davolls; A Ardern-Jones; R Eeles
Journal:  J Genet Couns       Date:  2007-05-11       Impact factor: 2.537

4.  Predictive testing for Huntington's disease: after the gene. The United Kingdom Huntington's Disease Prediction Consortium.

Authors:  S A Simpson; A E Harding
Journal:  J Med Genet       Date:  1993-12       Impact factor: 6.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.